Smith & Nephew plc
SNNHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeSmith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. Valued at $12.89B, SNN is a large-cap name in its sector. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Market Cap
$12.89B
Beta
0.68
P/E (TTM)
22.01
P/E (Fwd)
13.40
EPS (TTM)
$1.39
EPS (Fwd)
$2.28
ROE
11.8%
ROA
5.3%
Cash
$557.0M
Total Debt
$3.33B
Free CF
$876.6M
52W Change
1.4%
Annual Financials
Cash vs Debt
Smith & Nephew plc carries $3.33B in total debt against $557.0M in cash reserves — debt is roughly 6.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $876.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 11.8% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $5.21B to $6.16B.
The relatively low beta of 0.68 suggests SNN is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SNN.